CA2968180C — Dosing regimen for a selective s1p1 receptor agonist
Assigned to Actelion Pharmaceuticals Ltd · Expires 2020-01-28 · 6y expired
What this patent protects
The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3- o-tolyl-thiazolidin-4-one for use in the treatment of a disease or disorder associated with an activated immune system, such as psoriasis and mult…
USPTO Abstract
The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3- o-tolyl-thiazolidin-4-one for use in the treatment of a disease or disorder associated with an activated immune system, such as psoriasis and multiple sclerosis. The present invention provides a dosing regime by which adverse effects are minimized in subjections/patients during initiation of treatments, or upon re-initiation of treatment after drug discontinuation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.